Nicox Files NCX 470 NDA in China Through Ocumension
Sophia Antipolis, France, August 10, 2026 Nicox SA announced that its exclusive Chinese licensee Ocumension Therapeutics has submitted a...
CTCL
Advertisement
Innate Pharma to Advance Lacutamab Toward Phase 3 with Sobi
MARSEILLE, France, August 10, 2026 Innate Pharma SA announced plans to initiate the TELLOMAK-3 confirmatory Phase 3 study of...
Kyowa Kirin Reports Long-Term Survival Gains With Mogamulizumab
PRINCETON, N.J., June 30, 2026 Kyowa Kirin has announced new clinical analyses demonstrating that mogamulizumab continues to deliver meaningful...
BioInvent’s TNFR2 Antibody BI-1808 Shows Promising Responses in Advanced CTCL at EHA 2026
LUND, Sweden, June 11, 2026 BioInvent International AB presented new clinical data from its ongoing Phase 2a study evaluating...
BioInvent to Showcase BI-1206 and BI-1808 Hematology Progress at June KOL Event
LUND, Sweden, June 1, 2026 BioInvent International AB announced that it will host a key opinion leader (KOL) event...
Advertisements
BioInvent Reports Strong BI-1808 CTCL Responses at EHA
LUND, Sweden – May 12, 2026 BioInvent International AB announced new Phase 2a clinical data demonstrating that its investigational...
Citius Oncology Secures $36.5M for LYMPHIR Growth
CRANFORD, N.J., United States – May 5, 2026 Citius Oncology, Inc. has announced financing agreements totaling up to $36.5...
Citius Oncology Drives LYMPHIR Adoption in Cancer Care
CRANFORD, N.J., March 31, 2026 Citius Oncology, Inc. has reported strong early momentum following the U.S. launch of its...
EMA Positive Opinion Grants Orphan Drug Hope for CTCL Treatment
Dateline – November 17 2025 | Lund, Sweden BioInvent International AB (“BioInvent”), a clinical-stage biotech company focused on novel...
Advertisement
